BioCentury | Jun 16, 2020
Finance

eTheRNA’s €34M series B to support different take on COVID-19 vaccine, build out core cancer pipeline

The series B round for eTheRNA will fund the Belgian company’s core immuno-oncology pipeline as well as its different mRNA approach to combat the threat of coronaviruses. eTheRNA immunotherapies N.V. said Tuesday it raised €34...
BioCentury | May 21, 2020
Product Development

Translate Bio brings chronic disease-scale manufacturing to COVID-19 mRNA vaccine

Translate Bio and Sanofi’s bid to develop a COVID-19 mRNA vaccine highlights how manufacturing capacity is among the most visible differentiating factors at this stage in the pandemic counter-response. The partners’ program is one of...
BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

Dan Spiegelman stepped down as EVP and CFO at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to pursue other interests. SVP, Finance and Chief Accounting Officer Brian Mueller will serve as acting CFO as the rare diseases company...
BioCentury | Jan 6, 2020
Company News

Bancel letter showcases Moderna’s focus on mRNA vaccines

Moderna giving antiviral vaccines top billing in its sprawling mRNA pipeline reflects the growing consensus that the modality’s biggest near-term value lies in its potential to stoke immune responses. With 21 candidates spanning six treatment...
BioCentury | May 29, 2019
Company News

Management tracks: Gilead replaces Hamill with BMS's Mercier; plus Alnylam, Audentes and more

Gilead Sciences Inc. (NASDAQ:GILD) hired Johanna Mercier as chief commercial officer, effective July 1, to assume the responsibilities of Laura Hamill, who is leaving nine months after joining the company as EVP of worldwide commercial...
BioCentury | Dec 8, 2018
Finance

Moderna’s land grab

A blockbuster IPO by Moderna Inc. (NASDAQ:MRNA) gives the company the opportunity to make the case for mRNA. With more money, and a broader and more advanced pipeline than other players in the mRNA space,...
BioCentury | May 16, 2018
Company News

Management tracks: Novartis, Aileron

Novartis AG (NYSE:NVS; SIX:NOVN) said General Counsel Felix Ehrat will retire, effective June 1, in light of Novartis' payments to a consultancy owned by Michael Cohen. "As a co-signatory with our former CEO, I take...
BioCentury | Apr 7, 2017
Finance

Fast-growing evergreen

A larger and earlier than expected payout from Ogeda S.A. could substantially increase the size of Fund+’s evergreen life sciences fund, leading the firm to consider broadening its investment strategy. On April 3, Astellas Pharma...
BioCentury | Feb 25, 2017
Product Development

Getting the message

Hailed as a faster, cheaper way of producing therapeutic proteins than recombinant technologies, mRNA technologies have attracted some $2.5 billion from partnerships and investments from pharmas and VCs hoping to get in on the ground...
BioCentury | Jan 6, 2017
Company News

J&J reveals spate of partnerships

The Johnson & Johnson Innovation unit of Johnson & Johnson (NYSE:JNJ) unveiled a series of new partnerships Thursday, including collaborations in cancer, immunotherapy, and non-alcoholic steatohepatitis (NASH). Among the 15 deals, J&J's Janssen Pharmaceuticals unit...
Items per page:
1 - 10 of 15
BioCentury | Jun 16, 2020
Finance

eTheRNA’s €34M series B to support different take on COVID-19 vaccine, build out core cancer pipeline

The series B round for eTheRNA will fund the Belgian company’s core immuno-oncology pipeline as well as its different mRNA approach to combat the threat of coronaviruses. eTheRNA immunotherapies N.V. said Tuesday it raised €34...
BioCentury | May 21, 2020
Product Development

Translate Bio brings chronic disease-scale manufacturing to COVID-19 mRNA vaccine

Translate Bio and Sanofi’s bid to develop a COVID-19 mRNA vaccine highlights how manufacturing capacity is among the most visible differentiating factors at this stage in the pandemic counter-response. The partners’ program is one of...
BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

Dan Spiegelman stepped down as EVP and CFO at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to pursue other interests. SVP, Finance and Chief Accounting Officer Brian Mueller will serve as acting CFO as the rare diseases company...
BioCentury | Jan 6, 2020
Company News

Bancel letter showcases Moderna’s focus on mRNA vaccines

Moderna giving antiviral vaccines top billing in its sprawling mRNA pipeline reflects the growing consensus that the modality’s biggest near-term value lies in its potential to stoke immune responses. With 21 candidates spanning six treatment...
BioCentury | May 29, 2019
Company News

Management tracks: Gilead replaces Hamill with BMS's Mercier; plus Alnylam, Audentes and more

Gilead Sciences Inc. (NASDAQ:GILD) hired Johanna Mercier as chief commercial officer, effective July 1, to assume the responsibilities of Laura Hamill, who is leaving nine months after joining the company as EVP of worldwide commercial...
BioCentury | Dec 8, 2018
Finance

Moderna’s land grab

A blockbuster IPO by Moderna Inc. (NASDAQ:MRNA) gives the company the opportunity to make the case for mRNA. With more money, and a broader and more advanced pipeline than other players in the mRNA space,...
BioCentury | May 16, 2018
Company News

Management tracks: Novartis, Aileron

Novartis AG (NYSE:NVS; SIX:NOVN) said General Counsel Felix Ehrat will retire, effective June 1, in light of Novartis' payments to a consultancy owned by Michael Cohen. "As a co-signatory with our former CEO, I take...
BioCentury | Apr 7, 2017
Finance

Fast-growing evergreen

A larger and earlier than expected payout from Ogeda S.A. could substantially increase the size of Fund+’s evergreen life sciences fund, leading the firm to consider broadening its investment strategy. On April 3, Astellas Pharma...
BioCentury | Feb 25, 2017
Product Development

Getting the message

Hailed as a faster, cheaper way of producing therapeutic proteins than recombinant technologies, mRNA technologies have attracted some $2.5 billion from partnerships and investments from pharmas and VCs hoping to get in on the ground...
BioCentury | Jan 6, 2017
Company News

J&J reveals spate of partnerships

The Johnson & Johnson Innovation unit of Johnson & Johnson (NYSE:JNJ) unveiled a series of new partnerships Thursday, including collaborations in cancer, immunotherapy, and non-alcoholic steatohepatitis (NASH). Among the 15 deals, J&J's Janssen Pharmaceuticals unit...
Items per page:
1 - 10 of 15